Completion↦Quality and Risk↦Clinical Study Report↦Risk Reporting
Was betrifft es? Warum ist das wichtig?
A (final) Clinical Study Report (CSR) is an account describing in detail the methods, events and results of a study. The reporting of the risk management of the study is an important integral part of this document.
The CSR is written after the monitoring close-out visit has taken place, as the study is then closed and ready for the statistical analysis. Among other the report describes:
- The risk-based QMS implemented during the study
- Identified risks including applicable control measures
- Important deviations and remedial actions taken
The SP-INV submits the final CSR to the Ethics Committee (EC) and RA (e.g. Swissmedic), as applicable.
Was muss ich befolgen?
Based on the Risk Assessment Form (RAF):
- Describe the risk-based QMS implemented in your study
- Summarise important deviations and remedial actions taken
- If you have been audited include the audit certificate
- Complete other report sections and submit the report to the EC and RA (e.g. Swissmedic), as applicable
For studies with Medicinal Products, the CSR is submitted to the EC no later than 1 year upon study completion (i.e. last study participant has had his/her last study visit), or study discontinuation.
For non-clinical studies it is not necessary to submit a final report to the EC, except for some studies involving ionizing radiation.
For Medical Device or IVD studies consult respective articles in the ClinO-MD ordinance.
Wo kann ich Hilfe anfordern?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R2) – see in particular guidelines
- 1.6 Audit
- 5.0 Quality management
ISO 9001 (access liable to costs – see in particular section
- QMS Requirements
Swiss Law
ClinO – see in particular articles
- Art. 38 For the first visit and for completion, premature termination, interruption and resumption of a clinical trial
- Art. 44 For the use of ionising radiation
ClinO-MD – see in particular articles
- Art. 36 Notification of the completion, premature termination and interruption of a clinical trial
- Art. 39 Assessment, notification and reporting in relation to the use of ionising radiation
HRO – see in particular article
- Art. 22 Notification upon completion or premature termination of a research project